Holen Sie sich die Stockscreener-App
5.43
1.63%
-0.09
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$5.52
Offen:
$5.49
24-Stunden-Volumen:
3.33M
Relative Volume:
1.12
Marktkapitalisierung:
$566.58M
Einnahmen:
$409.00K
Nettoeinkommen (Verlust:
$-101.35M
KGV:
-3.311
EPS:
-1.64
Netto-Cashflow:
$-71.49M
1W Leistung:
+6.26%
1M Leistung:
+27.46%
6M Leistung:
-19.44%
1J Leistung:
-39.73%
1-Tages-Spanne:
$5.355
$5.56
1-Wochen-Bereich:
$5.00
$5.83
52-Wochen-Spanne:
$2.90
$9.59
Altimmune Inc Stock (ALT) Company Profile
Firmenname
Altimmune Inc
Sektor
Branche
Telefon
(240) 654-1450
Adresse
910 CLOPPER ROAD, GAITHERSBURG, MD
Vergleichen Sie ALT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ALT
Altimmune Inc
|
5.43 | 575.97M | 409.00K | -101.35M | -71.49M | -1.64 |
|
VRTX
Vertex Pharmaceuticals Inc
|
444.64 | 110.88B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
726.21 | 72.79B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
890.11 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
404.46 | 54.85B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
189.85 | 41.41B | 447.02M | -1.18B | -906.14M | -6.1812 |
Altimmune Inc Stock (ALT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-10 | Fortgesetzt | Goldman | Sell |
| 2025-02-28 | Eingeleitet | William Blair | Mkt Perform |
| 2025-01-08 | Eingeleitet | Stifel | Buy |
| 2024-11-12 | Eingeleitet | UBS | Buy |
| 2024-04-29 | Herabstufung | Guggenheim | Buy → Neutral |
| 2024-01-24 | Eingeleitet | Goldman | Neutral |
| 2023-03-22 | Herabstufung | Goldman | Buy → Neutral |
| 2022-12-01 | Eingeleitet | Goldman | Buy |
| 2021-12-29 | Fortgesetzt | Jefferies | Buy |
| 2021-06-02 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-02-11 | Eingeleitet | Guggenheim | Buy |
| 2020-12-14 | Eingeleitet | Jefferies | Buy |
| 2020-11-12 | Bestätigt | B. Riley Securities | Buy |
| 2020-09-25 | Eingeleitet | B. Riley FBR | Buy |
| 2020-08-14 | Eingeleitet | Evercore ISI | Outperform |
| 2020-07-31 | Eingeleitet | Piper Sandler | Overweight |
| 2020-07-28 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2020-02-24 | Fortgesetzt | ROTH Capital | Buy |
| 2019-07-19 | Eingeleitet | ROTH Capital | Buy |
| 2017-10-09 | Eingeleitet | Piper Jaffray | Overweight |
Alle ansehen
Altimmune Inc Aktie (ALT) Neueste Nachrichten
Levi & Korsinsky Notifies Altimmune, Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineALT - ACCESS Newswire
Altimmune Inc (HAM:3G0) Competitors 2025 - GuruFocus
Altimmune (HAM:3G0) ROA % : -36.91% (As of Sep. 2025) - GuruFocus
Altimmune (HAM:3G0) EV-to-EBIT : -4.00 (As of Dec. 08, 2025) - GuruFocus
Altimmune Inc (HAM:3G0) Stock Price, Trades & News - GuruFocus
Geode Capital Management LLC Raises Holdings in Altimmune, Inc. $ALT - MarketBeat
Altimmune: 48-Week MASH Data Due This Month Is Make Or Break For The Company (NASDAQ:ALT) - Seeking Alpha
EBITDA per share of Altimmune, Inc. – LSE:0A4C - TradingView
Stephen Durso Named CEO of Altimmune Inc. as Vipin Garg Steps Down - geneonline.com
Altimmune (ALT) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Durso succeeding Garg as Altimmune CEO - BioCentury
Altimmune releases additional phase 2 pemvidutide data for MASH - MSN
Altimmune (NASDAQ:ALT) Stock Price Down 6.6%Time to Sell? - MarketBeat
Investors SueWallSt as Altimmune, Inc. Faces Securities Fraud Allegations - The National Law Review
ALT SEC FilingsAltimmune 10-K, 10-Q, 8-K Forms - Stock Titan
Altimmune Announces CEO Transition and Succession Plan - The Globe and Mail
Key facts: Altimmune appoints Jerry Durso as CEO; pemvidutide trial data pending - TradingView
Altimmune announces CEO transition - MSN
Gaithersburg drug developer Altimmune names new CEO as current chief readies exit - The Business Journals
Altimmune stock falls after CEO Garg announces 2026 departure By Investing.com - Investing.com Canada
Altimmune stock falls after CEO Garg announces 2026 departure - Investing.com
Altimmune, Inc. Announces CEO Changes - marketscreener.com
Altimmune CEO Vipin Garg to Step Down - marketscreener.com
Altimmune names Jerry Durso as new CEO effective January 2026 By Investing.com - Investing.com Canada
Altimmune, Inc. Announces CEO Transition - TradingView
Altimmune names Jerry Durso as new CEO effective January 2026 - Investing.com
Altimmune (ALT) Announces CEO Transition Plan - GuruFocus
Altimmune falls as CEO Vipin Garg to step down - TradingView
Altimmune announces leadership change as CEO Vipin Garg steps down - Traders Union
Altimmune, Inc. Announces CEO Transition as Jerry Durso Succeeds Vipin Garg, Ph.D. - Quiver Quantitative
Altimmune announces CEO transition, succession plan - marketscreener.com
Altimmune Announces CEO Transition, Succession Plan - TradingView
Altimmune (Nasdaq: ALT) details CEO handover and late-stage pemvidutide path in MASH - Stock Titan
Intech Investment Management LLC Purchases 73,482 Shares of Altimmune, Inc. $ALT - MarketBeat
Altimmune Investors Drop Suit Over Liver Drug Trial, Stock Drop - Bloomberg Law News
Altimmune, Inc. (NASDAQ:ALT) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Altimmune to Participate in the Piper Sandler 37th Annual Healthcare Conference - The Manila Times
Altimmune (Nasdaq: ALT) to Present Chat at Piper Sandler 37th Healthcare Conference - Stock Titan
Wall Street Analysts Predict a 250.59% Upside in Altimmune (ALT): Here's What You Should Know - MSN
Altimmune Target of Unusually Large Options Trading (NASDAQ:ALT) - MarketBeat
ALT Stock Today (November 25, 2025): Altimmune Extends Rally as Pemvidutide Nears Critical FDA Moment - ts2.tech
Altimmune’s RECLAIM STUDY: A New Hope for Alcohol Use Disorder Treatment - MSN
Altimmune’s RESTORE TRIAL: A Promising Step in ALD Treatment - MSN
Net debt of Altimmune, Inc. – HAM:3G0 - TradingView
Altimmune Stock Attracts Strong Retail Buzz As Investors Count Down To 48-Week Data For Its Fatty Liver Treatment - MSN
Will Altimmune Inc. stock outperform international peersJuly 2025 Rallies & Low Drawdown Momentum Ideas - newser.com
While institutions invested in Altimmune, Inc. (NASDAQ:ALT) benefited from last week's 10% gain, individual investors stood to gain the most - simplywall.st
How Altimmune Inc. stock benefits from global expansion2025 Big Picture & Verified Entry Point Signals - newser.com
How strong is Altimmune Inc. stock revenue growthWeekly Trend Report & Accurate Intraday Trading Signals - newser.com
Transcript : Altimmune, Inc. Presents at Jefferies London Healthcare Conference 2025, Nov-20-2025 08 - MarketScreener
Altimmune at Jefferies Conference: Strategic Insights on Pemvidutide By Investing.com - Investing.com India
Finanzdaten der Altimmune Inc-Aktie (ALT)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.45%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):